STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALNY
  4. [8-K] ALNYLAM PHARMACEUTICALS, INC. Reports Material Event

Alnylam (NASDAQ: ALNY) outlines 2030 strategy and $2,987 million 2025 revenue

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Alnylam Pharmaceuticals reported preliminary 2025 global net product revenues of approximately $2,987 million for its four marketed RNAi medicines, with fourth-quarter revenues of about $995 million. Alongside these early figures, the company introduced a new five-year strategy called “Alnylam 2030”, which is intended to guide its next phase of growth. Alnylam also shared its product and pipeline goals for 2026 and issued full-year 2026 combined net product revenue guidance, with final audited 2025 results to follow in February 2026.

Positive

  • None.

Negative

  • None.

Insights

Alnylam pairs strong preliminary 2025 sales with a new 2030 strategy.

Alnylam Pharmaceuticals reported preliminary 2025 global net product revenues of approximately $2,987 million, including about $995 million in Q4, from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO. These figures indicate a substantial commercial base across its rare disease portfolio, though they remain unaudited and subject to adjustment.

The company simultaneously unveiled its five-year “Alnylam 2030” strategy and outlined 2026 product and pipeline goals, signaling a structured plan for both near-term development and commercialization. It also provided full-year 2026 combined net product revenue guidance, giving a forward-looking revenue framework.

Because the excerpt does not include year-over-year comparisons or the exact 2026 guidance range, the immediate financial impact is hard to quantify. The key elements to watch in the upcoming detailed 2025 results and guidance update in February 2026 will be how final audited revenues compare with these preliminary figures and how ambitious the 2026 revenue target appears relative to the current product base.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Understanding 8-K Material Events →
false0001178670January 11, 202600011786702026-01-112026-01-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 11, 2026

Alnylam Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
___________________________________________
Delaware
001-36407
77-0602661
(State or Other Jurisdiction
of Incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)

675 West Kendall Street,
Henri A. Termeer Square
 Cambridge, Massachusetts
02142
(Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (617) 551-8200
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
___________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)





☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock, $0.01 par value per shareALNYThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 2.02.Results of Operations and Financial Condition.
On January 11, 2026, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its new five-year strategy, “Alnylam 2030,” as well as its preliminary fourth quarter and full year 2025 global net product revenues of approximately $995 million and $2,987 million, respectively, for AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosiran) and OXLUMO® (lumasiran), and provided the Company’s 2026 product and pipeline goals. The Company also announced full year 2026 combined net product revenue guidance.
The preliminary selected financial results reported by the Company are unaudited, subject to adjustment, and provided as an approximation in advance of the Company’s announcement of complete financial results in February 2026.
The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.Financial Statements and Exhibits
(d)     Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1     Press Release dated January 11, 2026.
104     Cover Page Interactive Data File (embedded within the Inline XBRL document).





SIGNATURE
          Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 12, 2026
ALNYLAM PHARMACEUTICALS, INC.
By: /s/ Jeffrey V. Poulton
Jeffrey V. Poulton
Executive Vice President, Chief Financial Officer





Source: View Original Filing on SEC EDGAR

FAQ

What preliminary 2025 revenues did Alnylam (ALNY) report for its products?

Alnylam reported preliminary full-year 2025 global net product revenues of approximately $2,987 million for AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO.

How much preliminary revenue did Alnylam (ALNY) generate in Q4 2025?

For the fourth quarter of 2025, Alnylam reported preliminary global net product revenues of approximately $995 million for its four marketed products.

What is Alnylam’s new five-year strategy mentioned in the 8-K?

Alnylam announced a new five-year strategy called “Alnylam 2030”, intended to guide the company’s direction through the end of the decade.

Did Alnylam (ALNY) provide any 2026 guidance in this filing?

Yes, Alnylam provided full year 2026 combined net product revenue guidance, though the specific numbers are not included in this excerpt.

Are Alnylam’s 2025 financial figures in this report audited?

No. The selected 2025 figures are described as preliminary, unaudited and subject to adjustment, ahead of full results expected in February 2026.

What additional goals did Alnylam outline for 2026?

Alnylam outlined its 2026 product and pipeline goals, describing what it aims to achieve with its marketed medicines and development programs in that year.